Works by Bendell, Johanna C

Results: 52
    1
    2
    3

    Ramucirumab in Combination with Pembrolizumab in Treatment-Naïve Advanced Gastric or GEJ Adenocarcinoma: Safety and Antitumor Activity from the Phase 1a/b JVDF Trial.

    Published in:
    Cancers, 2020, v. 12, n. 10, p. 2985, doi. 10.3390/cancers12102985
    By:
    • Chau, Ian;
    • Penel, Nicolas;
    • Soriano, Andres O.;
    • Arkenau, Hendrik-Tobias;
    • Cultrera, Jennifer;
    • Santana-Davila, Rafael;
    • Calvo, Emiliano;
    • Le Tourneau, Christophe;
    • Zender, Lars;
    • Bendell, Johanna C.;
    • Mi, Gu;
    • Gao, Ling;
    • McNeely, Samuel Clark;
    • Oliveira, Joana M.;
    • Ferry, David;
    • Herbst, Roy S.;
    • Fuchs, Charles S.
    Publication type:
    Article
    4
    5
    6
    7

    Anal Cancer: An Overview.

    Published in:
    Oncologist, 2007, v. 12, n. 5, p. 524, doi. 10.1634/theoncologist.12-5-524
    By:
    • Uronis, Hope E.;
    • Bendell, Johanna C.
    Publication type:
    Article
    8
    9

    First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy.

    Published in:
    Cancer Management & Research, 2019, v. 11, p. 10463, doi. 10.2147/CMAR.S208720
    By:
    • Munster, Pamela;
    • Mita, Monica;
    • Mahipal, Amit;
    • Nemunaitis, John;
    • Massard, Christophe;
    • Mikkelsen, Tom;
    • Cruz, Cristina;
    • Paz-Ares, Luis;
    • Hidalgo, Manuel;
    • Rathkopf, Dana;
    • Jr, George Blumenschein;
    • Smith, David C;
    • Eichhorst, Barbara;
    • Cloughesy, Tim;
    • Filvaroff, Ellen H;
    • Li, Shaoyi;
    • Raymon, Heather;
    • Haan, Hans de;
    • Hege, Kristen;
    • Bendell, Johanna C
    Publication type:
    Article
    10
    11

    Safety and efficacy of nivolumab plus ipilimumab in patients with advanced renal cell carcinoma with brain metastases: CheckMate 920.

    Published in:
    Cancer (0008543X), 2022, v. 128, n. 5, p. 966, doi. 10.1002/cncr.34016
    By:
    • Emamekhoo, Hamid;
    • Olsen, Mark R.;
    • Carthon, Bradley C.;
    • Drakaki, Alexandra;
    • Percent, Ivor J.;
    • Molina, Ana M.;
    • Cho, Daniel C.;
    • Bendell, Johanna C.;
    • Gordan, Lucio N.;
    • Rezazadeh Kalebasty, Arash;
    • George, Daniel J.;
    • Hutson, Thomas E.;
    • Arrowsmith, Edward R.;
    • Zhang, Joshua;
    • Zoco, Jesus;
    • Johansen, Jennifer L.;
    • Leung, David K.;
    • Tykodi, Scott S.
    Publication type:
    Article
    12

    A phase I dose-escalation study to assess safety, tolerability, pharmacokinetics, and preliminary efficacy of the dual mTORC1/mTORC2 kinase inhibitor CC-223 in patients with advanced solid tumors or multiple myeloma.

    Published in:
    2015
    By:
    • Bendell, Johanna C.;
    • Kelley, Robin K.;
    • Shih, Kent C.;
    • Grabowsky, Jennifer A.;
    • Bergsland, Emily;
    • Jones, Suzanne;
    • Martin, Thomas;
    • Infante, Jeffrey R.;
    • Mischel, Paul S.;
    • Matsutani, Tomoo;
    • Xu, Shuichan;
    • Wong, Lilly;
    • Liu, Yong;
    • Wu, Xiaoling;
    • Mortensen, Deborah S.;
    • Chopra, Rajesh;
    • Hege, Kristen;
    • Munster, Pamela N.
    Publication type:
    journal article
    13
    14
    15
    16
    17
    18
    19
    20
    21

    A randomized phase II trial of nab‐paclitaxel and gemcitabine with tarextumab or placebo in patients with untreated metastatic pancreatic cancer.

    Published in:
    Cancer Medicine, 2019, v. 8, n. 11, p. 5148, doi. 10.1002/cam4.2425
    By:
    • Hu, Zishuo Ian;
    • Bendell, Johanna C.;
    • Bullock, Andrea;
    • LoConte, Noelle K.;
    • Hatoum, Hassan;
    • Ritch, Paul;
    • Hool, Hugo;
    • Leach, Joseph W.;
    • Sanchez, James;
    • Sohal, Davendra P. S.;
    • Strickler, John;
    • Patel, Ravindranath;
    • Wang‐Gillam, Andrea;
    • Firdaus, Irfan;
    • Yu, Kenneth H.;
    • Kapoun, Ann M.;
    • Holmgren, Eric;
    • Zhou, Lei;
    • Dupont, Jakob;
    • Picozzi, Vincent
    Publication type:
    Article
    22

    Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors [Corrigendum].

    Published in:
    International Journal of Nanomedicine, 2019, v. 14, p. 5751, doi. 10.2147/IJN.S207276
    By:
    • Wu, Huali;
    • Infante, Jeffrey R;
    • Keedy, Vicki L;
    • Jones, Suzanne F;
    • Chan, Emily;
    • Bendell, Johanna C;
    • Lee, Wooin;
    • Kirschbrown, Whitney P;
    • Zamboni, Beth A;
    • Ikeda, Satoshi;
    • Kodaira, Hiroshi;
    • Rothenberg, Mace L;
    • III, Howard A Burris;
    • Zamboni, William C
    Publication type:
    Article
    23

    Factors affecting the pharmacokinetics and pharmacodynamics of PEGylated liposomal irinotecan (IHL-305) in patients with advanced solid tumors.

    Published in:
    International Journal of Nanomedicine, 2015, v. 10, p. 1201, doi. 10.2147/IJN.S62911
    By:
    • Huali Wu;
    • Infante, Jeffrey R.;
    • Keedy, Vicki L.;
    • Jones, Suzanne F.;
    • chan, Emily;
    • Bendell, Johanna C.;
    • lee, Wooin;
    • Kirschbrown, Whitney P.;
    • Zamboni, Beth A.;
    • Ikeda, Satoshi;
    • Kodaira, Hiroshi;
    • Rothenberg, Mace L.;
    • Burris III, Howard A.;
    • Zamboni, William C.
    Publication type:
    Article
    24

    Treatment Rationale and Study Design for a Randomized, Double-Blind, Placebo-Controlled Phase II Study Evaluating Onartuzumab (MetMAb) in Combination With Bevacizumab Plus mFOLFOX-6 in Patients With Previously Untreated Metastatic Colorectal Cancer.

    Published in:
    Clinical Colorectal Cancer, 2013, v. 12, n. 3, p. 218, doi. 10.1016/j.clcc.2013.04.001
    By:
    • Bendell, Johanna C.;
    • Ervin, Thomas J.;
    • Gallinson, David;
    • Singh, Jaswinder;
    • Wallace, James A.;
    • Saleh, Mansoor N.;
    • Vallone, Marcy;
    • Phan, See-Chun;
    • Hack, Stephen P.
    Publication type:
    Article
    25

    Axitinib or Bevacizumab Plus FOLFIRI or Modified FOLFOX-6 After Failure of First-Line Therapy for Metastatic Colorectal Cancer: A Randomized Phase II Study.

    Published in:
    Clinical Colorectal Cancer, 2013, v. 12, n. 4, p. 239, doi. 10.1016/j.clcc.2013.09.001
    By:
    • Bendell, Johanna C.;
    • Tourmgand, Christophe;
    • Swieboda-Sadlej, Anna;
    • Barone, Carlo;
    • Wainberg, Zev A.;
    • Jong Gwang Kim;
    • Pencay, Carles;
    • Pastorelli, Davide;
    • Tarazi, Jamal;
    • Rosbrook, Brad;
    • Bloom, Joanna;
    • Ricart, Alejandro D.;
    • Kim, Sinil;
    • Sobrero, Alberto F.
    Publication type:
    Article
    26
    27

    Regorafenib Prior to Selective Internal Radiation Therapy Using <sup>90</sup>Y-Resin Microspheres for Refractory Metastatic Colorectal Cancer Liver Metastases: Analysis of Safety, Dosimetry, and Molecular Markers.

    Published in:
    Frontiers in Oncology, 2019, p. 1, doi. 10.3389/fonc.2019.00624
    By:
    • Kennedy, Andrew;
    • Shipley, Dianna;
    • Shpak, Max;
    • Blakely, Laura;
    • Hemphill, Brian;
    • Shih, Kent;
    • Lane, Cassie;
    • Zimmerman, Lisa;
    • McKenzie, Andrew;
    • Mainwaring, Mark;
    • Peyton, James D.;
    • Zubkus, John;
    • Wright, David;
    • Singh, Jaswinder;
    • Bendell, Johanna C.
    Publication type:
    Article
    28

    Atezolizumab in combination with bevacizumab enhances antigen-specific T-cell migration in metastatic renal cell carcinoma.

    Published in:
    Nature Communications, 2016, v. 7, n. 8, p. 12624, doi. 10.1038/ncomms12624
    By:
    • Wallin, Jeffrey J.;
    • Bendell, Johanna C.;
    • Funke, Roel;
    • Sznol, Mario;
    • Korski, Konstanty;
    • Jones, Suzanne;
    • Hernandez, Genevive;
    • Mier, James;
    • He, Xian;
    • Hodi, F. Stephen;
    • Denker, Mitchell;
    • Leveque, Vincent;
    • Cañamero, Marta;
    • Babitski, Galina;
    • Koeppen, Hartmut;
    • Ziai, James;
    • Sharma, Neeraj;
    • Gaire, Fabien;
    • Chen, Daniel S.;
    • Waterkamp, Daniel
    Publication type:
    Article
    29

    A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.

    Published in:
    International Journal of Cancer, 2016, v. 139, n. 1, p. 177, doi. 10.1002/ijc.30049
    By:
    • Eng, Cathy;
    • Bessudo, Alberto;
    • Hart, Lowell L.;
    • Severtsev, Aleksey;
    • Gladkov, Oleg;
    • Müller, Lothar;
    • Kopp, Mikhail V.;
    • Vladimirov, Vladimir;
    • Langdon, Robert;
    • Kotiv, Bogdan;
    • Barni, Sandro;
    • Hsu, Ching;
    • Bolotin, Ellen;
    • von Roemeling, Reinhard;
    • Schwartz, Brian;
    • Bendell, Johanna C.
    Publication type:
    Article
    30

    Effect of Celecoxib vs Placebo Added to Standard Adjuvant Therapy on Disease-Free Survival Among Patients With Stage III Colon Cancer: The CALGB/SWOG 80702 (Alliance) Randomized Clinical Trial.

    Published in:
    2021
    By:
    • Meyerhardt, Jeffrey A.;
    • Shi, Qian;
    • Fuchs, Charles S.;
    • Meyer, Jeffrey;
    • Niedzwiecki, Donna;
    • Zemla, Tyler;
    • Kumthekar, Priya;
    • Guthrie, Katherine A.;
    • Couture, Felix;
    • Kuebler, Philip;
    • Bendell, Johanna C.;
    • Kumar, Pankaj;
    • Lewis, Dequincy;
    • Tan, Benjamin;
    • Bertagnolli, Monica;
    • Grothey, Axel;
    • Hochster, Howard S.;
    • Goldberg, Richard M.;
    • Venook, Alan;
    • Blanke, Charles
    Publication type:
    journal article
    31
    32
    33
    34

    FOLFOXIRI‐Bevacizumab or FOLFOX‐Panitumumab in Patients with Left‐Sided RAS/BRAF Wild‐Type Metastatic Colorectal Cancer: A Propensity Score‐Based Analysis.

    Published in:
    Oncologist, 2021, v. 26, n. 4, p. 302, doi. 10.1002/onco.13642
    By:
    • Pietrantonio, Filippo;
    • Fucà, Giovanni;
    • Rossini, Daniele;
    • Schmoll, Hans‐Joachim;
    • Bendell, Johanna C.;
    • Morano, Federica;
    • Antoniotti, Carlotta;
    • Corallo, Salvatore;
    • Borelli, Beatrice;
    • Raimondi, Alessandra;
    • Marmorino, Federica;
    • Niger, Monica;
    • Boccaccino, Alessandra;
    • Masi, Gianluca;
    • Lonardi, Sara;
    • Boni, Luca;
    • Braud, Filippo;
    • Di Bartolomeo, Maria;
    • Falcone, Alfredo;
    • Cremolini, Chiara
    Publication type:
    Article
    35

    The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC).

    Published in:
    Oncologist, 2020, v. 25, n. 3, p. e451, doi. 10.1634/theoncologist.2019-0291
    By:
    • Bendell, Johanna C.;
    • Sauri, Tamara;
    • Gracián, Antonio Cubillo;
    • Alvarez, Rafael;
    • López‐López, Carlos;
    • García‐Alfonso, Pilar;
    • Hussein, Maen;
    • Miron, Maria‐Luisa Limon;
    • Cervantes, Andrés;
    • Montagut, Clara;
    • Vivas, Cristina Santos;
    • Bessudo, Alberto;
    • Plezia, Patricia;
    • Moons, Veerle;
    • Andel, Johannes;
    • Bennouna, Jaafar;
    • Westhuizen, Andre;
    • Samuel, Leslie;
    • Rossomanno, Simona;
    • Boetsch, Christophe
    Publication type:
    Article
    36
    37

    A Randomized, Double-Blinded, Phase II Trial of Gemcitabine and Nab-Paclitaxel Plus Apatorsen or Placebo in Patients with Metastatic Pancreatic Cancer: The RAINIER Trial.

    Published in:
    Oncologist, 2017, v. 22, n. 12, p. 1427, doi. 10.1634/theoncologist.2017-0066
    By:
    • Ko, Andrew H.;
    • Murphy, Patrick B.;
    • Peyton, James D.;
    • Shipley, Dianna L.;
    • Al‐Hazzouri, Ahmed;
    • Rodriguez, Francisco A.;
    • Womack, Mark S.;
    • Xiong, Henry Q.;
    • Waterhouse, David M.;
    • Tempero, Margaret A.;
    • Guo, Shuangli;
    • Lane, Cassie M.;
    • Earwood, Chris;
    • DeBusk, Laura M.;
    • Bendell, Johanna C.
    Publication type:
    Article
    38
    39

    A Phase II Randomized Trial (GO27827) of First-Line FOLFOX Plus Bevacizumab with orWithout the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer.

    Published in:
    Oncologist, 2017, v. 22, n. 3, p. 264, doi. 10.1634/theoncologist.2016-0223
    By:
    • Bendell, Johanna C.;
    • Hochster, Howard;
    • Hart, Lowell L.;
    • Firdaus, Irfan;
    • Mace, Joseph R.;
    • McFarlane, Joshua J.;
    • Kozloff, Mark;
    • Catenacci, Daniel;
    • Hsu, Jessie J.;
    • Hack, Stephen P.;
    • Shames, David S.;
    • Phan, See‐Chun;
    • Koeppen, Hartmut;
    • Cohn, Allen L.
    Publication type:
    Article
    40
    41

    A Phase II Study of Capecitabine, Oxaliplatin, and Bevacizumab in the Treatment of Metastatic Esophagogastric Adenocarcinomas.

    Published in:
    Oncologist, 2013, v. 18, n. 3, p. 271, doi. 10.1634/theoncologist.2012-0404
    By:
    • Uronis, Hope E.;
    • Bendell, Johanna C.;
    • Altomare, Ivy;
    • Blobe, Gerard C.;
    • Hsu, S. David;
    • Morse, Michael A.;
    • Pang, Herbert;
    • Zafar, S. Yousuf;
    • Conkling, Paul;
    • Favaro, Justin;
    • Arrowood, Christy C.;
    • Cushman, Stephanie M.;
    • Meadows, Kellen L.;
    • Brady, John C.;
    • Nixon, Andrew B.;
    • Hurwitz, Herbert I.
    Publication type:
    Article
    42

    Treatment Patterns and Clinical Outcomes in Patients With Metastatic Colorectal Cancer Initially Treated with FOLFOX-Bevacizumab or FOLFIRI-Bevacizumab: Results From ARIES, a Bevacizumab Observational Cohort Study.

    Published in:
    Oncologist, 2012, v. 17, n. 12, p. 1486, doi. 10.1634/theoncologist.2012-0190
    By:
    • Bendell, Johanna C.;
    • Bekaii-Saab, Tanios S.;
    • Cohn, Allen L.;
    • Hurwitz, Herbert I.;
    • Kozloff, Mark;
    • Tezcan, Haluk;
    • Roach, Nancy;
    • Mun, Yong;
    • Fish, Susan;
    • Flick, E. Dawn;
    • Dalal, Darshan;
    • Grothey, Axel
    Publication type:
    Article
    43

    Targeted Therapy in Rectal Cancer.

    Published in:
    Oncology (08909091), 2007, v. 21, n. 9, p. 1055
    By:
    • Willett, Christopher G.;
    • Duda, Dan G.;
    • Czito, Brian G.;
    • Bendell, Johanna C.;
    • Clark, Jeffrey W.;
    • Jain, Rakesh K.
    Publication type:
    Article
    44

    A phase Ib open-label dose escalation study of the safety, pharmacokinetics, and pharmacodynamics of cobimetinib (GDC-0973) and ipatasertib (GDC-0068) in patients with locally advanced or metastatic solid tumors.

    Published in:
    Investigational New Drugs, 2021, v. 39, n. 1, p. 163, doi. 10.1007/s10637-020-00975-6
    By:
    • Shapiro, Geoffrey I.;
    • LoRusso, Patricia;
    • Cho, Daniel C.;
    • Musib, Luna;
    • Yan, Yibing;
    • Wongchenko, Matthew;
    • Chang, Ilsung;
    • Patel, Premal;
    • Chan, Iris T.;
    • Sanabria-Bohorquez, Sandra;
    • Meng, Raymond D.;
    • Bendell, Johanna C.
    Publication type:
    Article
    45

    A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancer.

    Published in:
    Investigational New Drugs, 2020, v. 38, n. 4, p. 1145, doi. 10.1007/s10637-019-00873-6
    By:
    • Bendell, Johanna C.;
    • Bischoff, Helge G.;
    • Hwang, Jimmy;
    • Reinhardt, Hans Christian;
    • Zander, Thomas;
    • Wang, Xuejing;
    • Hynes, Scott;
    • Pitou, Celine;
    • Campbell, Robert;
    • Iversen, Philip;
    • Farrington, Daphne L.;
    • Bell-McGuinn, Katherine;
    • Thomas, Michael
    Publication type:
    Article
    46
    47
    48
    49
    50